Business
Pre close statement
Pre close statement.
About this update from Genedrive Plc
[{"type":"text","content":"\n RNS Number : 1193Q Epistem Holdings plc 29 July 2010 \n \n\nEpistem Holdings Plc\n(\"Epistem\" or \"the Company\")\nPre-Close Trading Update \nEpistem (AIM: EHP), the rapidly growing biotechnology company, today announces a pre-close trading statement for the year ended 30th June 2010.\nFollowing a very positive year during which sales in all of the Company's business divisions have made strong progress, the Company is pleased to announce that trading over the year was in line with market forecasts and the Company expects to report growth in year on year after tax profit. \nThe Company expects to release its final results for the year ended 30th June 2010 on Tuesday 5th October 2010 and will hold an analysts' meeting on the day.\nFor further information contact:\nEpistem Plc\nMatthew Walls, Chief Executive Officer ++44 161 606 7258 John Rylands, Chief Financial Officer\nKBC Peel Hunt Ltd\nNominated Adviser: James Steel/Vijay Barathan ++44 207 418 8900 \nDefacto Communications \nMike Wort/Anna Dunphy ++44 207 861 3838\nNotes for editors\nEpistem is a biotechnology company commercialising its expertise in epithelial stem cells in the areas of oncology, gastrointestinal and dermatological diseases. Epistem develops innovative therapeutics, biomarkers and diagnostics alongside providing contract research services to drug development companies. The Group'...